Radio and PodcastLive Radio & PodcastsLoading episode
Fetching episode details...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & Podcasts
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
MET-Amplified Lung Cancer: A New Target for XALKORI? is an episode from GRACEcast by Howard (Jack) West, MD. Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positiv...
This episode belongs to GRACEcast.
Use the player on this page to stream the episode online.
Published Jul 3, 2014, 07:18 long, audio available.
Continue listening to more episodes from GRACEcast.
Jul 29, 2014 - 01:55
Jul 24, 2014 - 02:03
Jul 20, 2014 - 04:40
Jul 15, 2014 - 03:15